{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:59:23Z","timestamp":1774537163479,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s12029-022-00891-3","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T22:09:04Z","timestamp":1669759744000},"page":"712-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Utilizing Patient-Derived Organoids in the Management of Colorectal Cancer with Peritoneal Metastases: A Review of Current Literature"],"prefix":"10.1007","volume":"54","author":[{"given":"Richard A.","family":"Erali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Gironda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia R.","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem","family":"Wajih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay","family":"Soker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos I.","family":"Votanopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"1","key":"891_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"891_CR2","unstructured":"U.S. Cancer Statistics Working Group. U.S. Department of Health and Human Services, C.f.D.C.a.P.a.N.C.I. U.S. cancer statistics data visualizations tool, based on 2021 submission data (1999\u20132019). 1999\u20132019 [cited 2022 November 6, 2022]. Available from: www.cdc.gov\/cancer\/dataviz."},{"issue":"3","key":"891_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145\u201364.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"891_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545\u201350.","journal-title":"Br J Surg"},{"issue":"22","key":"891_CR5","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","volume":"23","author":"G Colucci","year":"2005","unstructured":"Colucci G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell\u2019Italia Meridionale. J Clin Oncol. 2005;23(22):4866\u201375.","journal-title":"J Clin Oncol"},{"issue":"4","key":"891_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1055\/s-0029-1242465","volume":"22","author":"RA Goodwin","year":"2009","unstructured":"Goodwin RA, Asmis TR. Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg. 2009;22(4):251\u20136.","journal-title":"Clin Colon Rectal Surg"},{"issue":"6","key":"891_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/jso.21679","volume":"102","author":"PH Sugarbaker","year":"2010","unstructured":"Sugarbaker PH, et al. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576\u201381.","journal-title":"J Surg Oncol"},{"issue":"1","key":"891_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","volume":"43","author":"V Leung","year":"2017","unstructured":"Leung V, et al. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(1):144\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"891_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jso.25277","volume":"119","author":"NA Alzahrani","year":"2019","unstructured":"Alzahrani NA, et al. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional experience. J Surg Oncol. 2019;119(3):336\u201346.","journal-title":"J Surg Oncol"},{"issue":"4","key":"891_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/ASO.2004.08.014","volume":"11","author":"VJ Verwaal","year":"2004","unstructured":"Verwaal VJ, et al. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11(4):375\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"891_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ejso.2015.05.018","volume":"41","author":"TR van Oudheusden","year":"2015","unstructured":"van Oudheusden TR, et al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review. Eur J Surg Oncol. 2015;41(10):1269\u201377.","journal-title":"Eur J Surg Oncol"},{"key":"891_CR12","doi-asserted-by":"crossref","unstructured":"Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int J Mol Sci.\u00a02020;21(15).","DOI":"10.3390\/ijms21155311"},{"key":"891_CR13","doi-asserted-by":"crossref","unstructured":"de Reynies A, et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol.\u00a02008;26(13):2228\u201330; author reply 2230\u20131.","DOI":"10.1200\/JCO.2007.15.9186"},{"issue":"14","key":"891_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408\u201317.","journal-title":"N Engl J Med"},{"issue":"5","key":"891_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","volume":"51","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio F, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587\u201394.","journal-title":"Eur J Cancer"},{"issue":"12","key":"891_CR16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/bjc.2015.173","volume":"112","author":"A Rowland","year":"2015","unstructured":"Rowland A, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888\u201394.","journal-title":"Br J Cancer"},{"key":"891_CR17","doi-asserted-by":"crossref","unstructured":"Middha S, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol.\u00a02017.","DOI":"10.1200\/PO.17.00084"},{"issue":"11","key":"891_CR18","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/nm.4191","volume":"22","author":"RJ Hause","year":"2016","unstructured":"Hause RJ, et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342\u201350.","journal-title":"Nat Med"},{"issue":"1","key":"891_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","volume":"5","author":"GE Wensink","year":"2021","unstructured":"Wensink GE, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis Oncol. 2021;5(1):30.","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"891_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"891_CR21","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1245\/s10434-019-08143-8","volume":"27","author":"KI Votanopoulos","year":"2020","unstructured":"Votanopoulos KI, et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. Ann Surg Oncol. 2020;27(6):1956\u201367.","journal-title":"Ann Surg Oncol"},{"key":"891_CR22","doi-asserted-by":"crossref","unstructured":"Ooft SN, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med.\u00a02019;11(513).","DOI":"10.1126\/scitranslmed.aay2574"},{"issue":"9","key":"891_CR23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112\u201329.","journal-title":"Cancer Discov"},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.semcancer.2018.06.005","volume":"53","author":"PW Nagle","year":"2018","unstructured":"Nagle PW, et al. Patient-derived tumor organoids for prediction of cancer treatment response. Semin Cancer Biol. 2018;53:258\u201364.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"891_CR25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/s41416-022-01742-5","volume":"126","author":"J Laoukili","year":"2022","unstructured":"Laoukili J, et al. Peritoneal metastases from colorectal cancer belong to consensus molecular subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. Br J Cancer. 2022;126(12):1824\u201333.","journal-title":"Br J Cancer"},{"issue":"13","key":"891_CR26","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe SD, et al. Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27(13):4950\u201360.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"891_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s10439-019-02269-2","volume":"48","author":"S Forsythe","year":"2020","unstructured":"Forsythe S, et al. Development of a colorectal cancer 3D micro-tumor construct platform from cell lines and patient tumor biospecimens for standard-of-care and experimental drug screening. Ann Biomed Eng. 2020;48(3):940\u201352.","journal-title":"Ann Biomed Eng"},{"issue":"2","key":"891_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet F, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol"},{"issue":"14","key":"891_CR29","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1158\/1078-0432.CCR-20-0073","volume":"26","author":"V Narasimhan","year":"2020","unstructured":"Narasimhan V, et al. Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clin Cancer Res. 2020;26(14):3662\u201370.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"891_CR30","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106(10):1404\u201314.","journal-title":"Br J Surg"},{"issue":"1","key":"891_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13046-016-0475-z","volume":"36","author":"F Bozzi","year":"2017","unstructured":"Bozzi F, et al. MIF\/CD74 axis is a target for novel therapies in colon carcinomatosis. J Exp Clin Cancer Res. 2017;36(1):16.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"891_CR32","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350\u20136.","journal-title":"Nat Med"},{"issue":"9","key":"891_CR33","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamaoncol.2016.2314","volume":"2","author":"N Song","year":"2016","unstructured":"Song N, et al. Clinical outcome from oxaliplatin treatment in stage II\/III colon cancer according to intrinsic subtypes: secondary analysis of NSABP C-07\/NRG oncology randomized clinical trial. JAMA Oncol. 2016;2(9):1162\u20139.","journal-title":"JAMA Oncol"},{"issue":"3","key":"891_CR34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41418-017-0011-5","volume":"25","author":"JF Linnekamp","year":"2018","unstructured":"Linnekamp JF, et al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differ. 2018;25(3):616\u201333.","journal-title":"Cell Death Differ"},{"issue":"13","key":"891_CR35","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1245\/s10434-020-08841-8","volume":"27","author":"O Moaven","year":"2020","unstructured":"Moaven O, et al. Clinical implications of genetic signatures in appendiceal cancer patients with incomplete cytoreduction\/HIPEC. Ann Surg Oncol. 2020;27(13):5016\u201323.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"891_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11605-020-04886-y","volume":"25","author":"M Garland-Kledzik","year":"2021","unstructured":"Garland-Kledzik M, et al. Prognostic impact and utility of immunoprofiling in the selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC). J Gastrointest Surg. 2021;25(1):233\u201340.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"891_CR37","first-page":"668","volume":"6","author":"BE Sylvester","year":"2015","unstructured":"Sylvester BE, Vakiani E. Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. J Gastrointest Oncol. 2015;6(6):668\u201375.","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"891_CR38","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1634\/theoncologist.2008-0181","volume":"13","author":"D Santini","year":"2008","unstructured":"Santini D, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13(12):1270\u20135.","journal-title":"Oncologist"},{"issue":"15","key":"891_CR39","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-19-3637","volume":"26","author":"J Bruun","year":"2020","unstructured":"Bruun J, et al. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin Cancer Res. 2020;26(15):4107\u201319.","journal-title":"Clin Cancer Res"},{"key":"891_CR40","doi-asserted-by":"crossref","unstructured":"Forsythe S, et al. Patient specific sarcoma organoids for personalized translational research: unification of the operating room with rare cancer research and clinical implications. Ann Surg Oncol.\u00a02022.","DOI":"10.1245\/s10434-022-12086-y"},{"issue":"1","key":"891_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1084\/jem.145.1.204","volume":"145","author":"RW Orkin","year":"1977","unstructured":"Orkin RW, et al. A murine tumor producing a matrix of basement membrane. J Exp Med. 1977;145(1):204\u201320.","journal-title":"J Exp Med"},{"issue":"5","key":"891_CR42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.semcancer.2005.05.004","volume":"15","author":"HK Kleinman","year":"2005","unstructured":"Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005;15(5):378\u201386.","journal-title":"Semin Cancer Biol"},{"key":"891_CR43","unstructured":"Corning. Corning\u00ae Matrigel\u00ae basement membrane matrix. 2022.\u00a0Available from: https:\/\/certs-ecatalog.corning.com\/life-sciences\/product-descriptions\/354230.pdf."},{"key":"891_CR44","doi-asserted-by":"crossref","unstructured":"Polykandriotis E, et al.\u00a0To Matrigel or not to Matrigel. Am J Pathol\u00a02008;172(5):1441; author reply 1441\u20132.","DOI":"10.2353\/ajpath.2008.071215"},{"key":"891_CR45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.matbio.2016.06.002","volume":"57\u201358","author":"R Cruz-Acuna","year":"2017","unstructured":"Cruz-Acuna R, Garcia AJ. Synthetic hydrogels mimicking basement membrane matrices to promote cell-matrix interactions. Matrix Biol. 2017;57\u201358:324\u201333.","journal-title":"Matrix Biol"},{"issue":"7","key":"891_CR46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41578-020-0199-8","volume":"5","author":"EA Aisenbrey","year":"2020","unstructured":"Aisenbrey EA, Murphy WL. Synthetic alternatives to Matrigel. Nat Rev Mater. 2020;5(7):539\u201351.","journal-title":"Nat Rev Mater"},{"issue":"1","key":"891_CR47","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/aae543","volume":"11","author":"A Mazzocchi","year":"2018","unstructured":"Mazzocchi A, et al. Optimization of collagen type I-hyaluronan hybrid bioink for 3D bioprinted liver microenvironments. Biofabrication. 2018;11(1): 015003.","journal-title":"Biofabrication"},{"issue":"9","key":"891_CR48","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/bit.25950","volume":"113","author":"A Skardal","year":"2016","unstructured":"Skardal A, et al. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol Bioeng. 2016;113(9):2020\u201332.","journal-title":"Biotechnol Bioeng"},{"issue":"18","key":"891_CR49","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-21-0982","volume":"27","author":"SD Forsythe","year":"2021","unstructured":"Forsythe SD, et al. Organoid platform in preclinical investigation of personalized immunotherapy efficacy in appendiceal cancer: feasibility study. Clin Cancer Res. 2021;27(18):5141\u201350.","journal-title":"Clin Cancer Res"},{"key":"891_CR50","doi-asserted-by":"crossref","unstructured":"Thalheim T, et al. Epigenetic drifts during long-term intestinal organoid culture. Cells.\u00a02021;10(7).","DOI":"10.3390\/cells10071718"},{"issue":"6","key":"891_CR51","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1245\/s10434-022-11441-3","volume":"29","author":"CD Valenzuela","year":"2022","unstructured":"Valenzuela CD, et al. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for cancers with peritoneal metastasis: a 30-year institutional experience. Ann Surg Oncol. 2022;29(6):3436\u201345.","journal-title":"Ann Surg Oncol"},{"key":"891_CR52","doi-asserted-by":"crossref","unstructured":"Sachs N, et al.\u00a0A living biobank of breast cancer organoids captures disease heterogeneity. Cell.\u00a02018;172(1\u20132):373\u2013386 e10.","DOI":"10.1016\/j.cell.2017.11.010"},{"issue":"3","key":"891_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/SLA.0000000000004200","volume":"272","author":"TT Seppala","year":"2020","unstructured":"Seppala TT, et al. Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer. Ann Surg. 2020;272(3):427\u201335.","journal-title":"Ann Surg"},{"issue":"6378","key":"891_CR54","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920\u20136.","journal-title":"Science"},{"key":"891_CR55","unstructured":"3D PC-TG. CellTiter-Glo\u00ae 3D cell viability assay. 2022; Available from: https:\/\/www.promega.com\/products\/cell-health-assays\/cell-viability-and-cytotoxicity-assays\/celltiter-glo-3d-cell-viability-assay\/?catNum=G9681."},{"issue":"1","key":"891_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","volume":"8","author":"WA Hammond","year":"2016","unstructured":"Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57\u201384.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-022-00891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-022-00891-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-022-00891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T07:36:14Z","timestamp":1698478574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-022-00891-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s12029-022-00891-3","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"20 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}